Skip to main content

Table 2 Analysis of the effects of phenotypes on TTF and OS.

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Genotype N % Median TTF
(months)
p value Median OS
(months)
p value
CYP2C19       
EM 266 78 28.7 0.4
(0.4)
73.9 0.4
(0.5)
IM + PM 73 22 25.1   65.6  
CYP2D6       
UM + EM 127 56 30.7 0.9
(0.8)
65.9 0.2
(0.4)
IM + PM 101 44 25.4   80.7  
  1. Values in italics are adjusted for prognostic-related factors (TTF: β2-microglobulin.
  2. OS: β2-microglobulin, creatinine and Durie-Salmon stage) and are shown in parentheses.